Research firm sees Humira as successor to Lipitor's blockbuster throne

05/3/2010 | Wall Street Journal, The

EvaluatePharma predicted that Abbott Laboratories and Eisai's rheumatoid arthritis medicine Humira will replace Pfizer's Lipitor as the world's best-selling drug after the cholesterol treatment's patent expires next year. Although Humira is not likely to surpass Lipitor's $13.7 billion in sales in 2006, it is expected to generate $10.1 billion by 2016, the research firm said, followed by Roche Holding's cancer drug Avastin at $8.9 billion.

View Full Article in:

Wall Street Journal, The